[#DIV28SUPER] UF POSTDOCTORAL ASSOCIATE POSITION IN BEHAVIORAL ECONOMIC HEALTH RESEARCH

Postdoctoral associate position in behavioral economic health research 

The University of Florida Center for Behavioral Economic Health Research (CBEHR), based in the College of Health & Human Performance and Department of Health Education & Behavior, seeks a postdoctoral research associate to begin in 2023 (start date negotiable). The CBEHR is guided by the trans-discipline of behavioral economics and houses research, applications, and educational initiatives promoting beneficial health behavior change. Research areas include substance misuse; HIV, STI and sexual risk behaviors; physical inactivity; and unhealthy eating behaviors (CBEHR Faculty). The postdoctoral associate will gain skills and expertise to be an independent investigator through participation in research, manuscript preparation, grant development, seminars, and other Center activities.  

This time-limited 12-month, non-tenure track position has an initial 2-year appointment, conditional on satisfactory performance. Compensation is competitive with NIH postdoctoral fellowship stipend levels. Appointment continuation is contingent upon funding availability, center/department needs, and satisfactory performance. 

Job qualifications: Doctoral degree (or earning degree by start date) in psychology, public health, or a related social/behavioral science with demonstrated interest in a research career and a record of research productivity. Candidates with quantitative methods training and research experience in behavioral economics, substance misuse, other addictive and related risk behaviors (e.g., sexual risk behaviors) are preferred. Candidates from diverse backgrounds are encouraged to apply.  

Apply at Careers at UF, job number 525376: https://explore.jobs.ufl.edu/en-us/job/525376/postdoctoral-research-associate. Submit a CV and cover letter describing your research experience and interests. Applications will be reviewed until the position is filled. An official transcript must be provided upon hire.   

The University of Florida is An Equal Employment Opportunity Institution. If a disability accommodation is needed to apply, please call 352/392-2477 or the Florida Relay System at 800/955-8771 (TDD). Hiring contingent upon eligibility to work in the US. Searches are conducted in accordance with Florida's Sunshine Law.  

_______________________________

Meredith S. Berry, Ph.D.

Assistant Professor

Department of Health Education and Behavior

Department of Psychology

University of Florida

Gainesville, Florida 32611

Email: mberry@ufl.edu

[#DIV28SUPER] Post-Doc Opportunity at Johns Hopkins

All,

See ad below for post-doc opportunity at JHU/BPRU.  Please feel free to share with anyone you think might be interested.

-Ryan 

Johns Hopkins Behavioral Pharmacology Research Unit (BPRU)

Postdoctoral Fellowship Opening

 

The Johns Hopkins University School of Medicine invites applications for postdoctoral research fellowships at the Behavioral Pharmacology Research Unit (BPRU) within the Department of Psychiatry and Behavioral Sciences. Fellows receive research training in the clinical pharmacology of substance use including human laboratory drug administration studies and clinical treatment trials. Fellows benefit from experienced faculty and a NIDA-funded T32 training grant with a productive 40+ year history and over 130 graduates. Non-T32 supported training slots are also available for selected areas. Fellows work closely with faculty mentors to gain practical research experience and develop as productive independent scholars. Job responsibilities vary but generally include training in the management and supervision in the conduct of human laboratory and randomized trial studies, conducting data analyses, preparing manuscripts, and presenting at national and international conferences. Trainees from the program are highly successful, and have been hired by the FDA, DEA, NIH, research universities, teaching colleges, industry, and private businesses upon training completion.

Areas of Interest: Opportunities include research related to a variety of psychoactive drug classes, but the current position would be predominantly focused on research related to cannabis/cannabinoids, nicotine/tobacco, and/or alcohol.  Research projects include human behavioral pharmacology studies that utilize a variety of research methodologies including acute drug administration, cognitive and psychomotor performance, simulated driving, regulatory science, observational and natural history assessments including ecological momentary assessment (EMA), toxicology/pharmacokinetics, and clinical trials. For more information about the Cannabis Science Laboratory, visit our website: https://jhcannabissciencelab.com. Funding for the position is supported by a NIDA-funded T32 training grant.

 

Eligibility: Eligible applicants for T32 slots must be a U.S. citizen or permanent resident. All applicants must have completed doctoral degree requirements (e.g., PhD, MD, DO, PsyD) prior to starting at the BPRU. Many training backgrounds are appropriate, including experimental or clinical psychology, pharmacology, toxicology, preclinical science, psychiatry or other medicine, neuroscience, nursing, public health, and social work. Prior experience with human or nonhuman research is appropriate. The BPRU is particularly interested in candidates who can contribute to the diversity and excellence of our research program. Applications from persons with disabilities, protected veterans, and persons underrepresented in science are strongly encouraged.

 

Start date: Ideal candidate will be able to start by June 30^th 2023, but other applicants will be considered

Email: BPRUpostdocprogram@jh.edu and copy Ryan Vandrey (rvandrey@jhmi.edu) and Tory Spindle (tspindle@jhmi.edu)

Or apply online:  https://www.hopkinsmedicine.org/psychiatry/research/BPRU/fellowshipsBPRU.html

BPRU Website: https://www.hopkinsmedicine.org/psychiatry/research/BPRU/

Cannabis Science Lab Website: https://jhcannabissciencelab.com

[#DIV28SUPER] Accepting T32 Post-Docs at Columbia University (Division on Substance Use Disorders)

Hello all, 

I'm sending this on behalf of Jermaine Jones. 

The Division on Substance Use Disorders at the Columbia University Department of Psychiatry/New York State Psychiatric Institute is accepting applications for NIDA T32 Post-Doc positions. 

See the attached for full details about the positions.

Matthew Kirkpatrick, PhD

Associate Professor of Research, Department of Population and Public Health Sciences

USC Drug Use & Behavior Laboratory (PI)

https://dublab.usc.edu/

Keck School of Medicine

University of Southern California

Phone: 323-442-8221

[#DIV28SUPER] NIDA Neuroscience Update, January 18, 2023

Table of Contents:

I.                    Virtual NIH Grants Conference & PreCon Events, February 1-2, 2023

II.                  Notice of Special Interest (NOSI): Effects of Cannabis Use and Cannabinoids on the Developing Brain

III.                Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) (RFA-DA-24-007)

IV.                Mechanisms and Targets at the Intersection of HIV and Substance Use (R01 Clinical Trials Not Allowed) (RFA-DA-24-013)

V.                  Mechanisms and Targets at the Intersection of HIV and Substance Use (R21 Clinical Trials Not Allowed) (RFA-DA-24-014)

VI.                Notice of Special Interest (NOSI) Targeting Epigenetic Regulators for Treating Addiction and Substance Use Disorders (NOT-DA-24-004)

VII.              Notice of Special Interest (NOSI): Chemoproteomic Approaches for Discovery of Targets and Therapeutics to Treat Substance Use Disorders (NOT-DA-24-005)

VIII.            Targeting Inflammasomes in Substance Abuse and HIV (R01 and R21, Clinical Trial Not Allowed). (RFA-DA-24-003) and (RFA-DA-24-004)

IX.                Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed). (RFA-DA-24-002).

X.                  Other NIDA Funding Opportunities - National Institute on Drug Abuse

XI.                NIDA Division of Therapeutics and Medical Consequences (DTMC) Supervisory Health Scientist Administrator (Branch Chief) Substance Use Disorders 

 

I.                    Virtual NIH Grants Conference & PreCon Events, February 1-2, 2023

Please join us at the 2023 Virtual NIH Grants Conference: Funding, Policies, & Process that will take place Wednesday, Feb 1 – Thursday, Feb 2. The conference will cover topics including: Navigating Early Career Funding Opportunities; NIH Loan Repayment Programs; forging International Collaborations; Human Subjects Research; and Research Misconduct and Detrimental Research Practices. NIDA program officers, grants management specialists, and scientific review officers will be available for 20 minute appointments during the 2-day conference to answer your questions via the 1:1 Meet the Experts event. We look forward to seeing you there.

 

-------------------------------------------------------------------------------------------------------------------------------

II.                  Notice of Special Interest (NOSI): Effects of Cannabis Use and Cannabinoids on the Developing Brain.  Notice Number: NOT-DA-20-039

 

The purpose of this Notice is to encourage investigators to submit grant applications to the National Institute on Drug Abuse (NIDA)to study the effects of cannabis and cannabinoid exposure on the developing brain, from pre-, peri-, and post-natal development through young adulthood in humans and using animal models.

 

Application Dates: Standard dates apply

 

-------------------------------------------------------------------------------------------------------------------------------

III.                Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) (RFA-DA-24-007)

 

The purpose of this award is to support early stage investigators proposing highly innovative research in the area of chemistry and pharmacology of substance use disorders and addiction. This award is to support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. The research may focus on development of novel chemical, pharmacological, or computational methods and tools that can potentially be applied to investigate basic mechanisms, targets, and pathways of relevance to treating addiction and substance use disorders. Investigators outside the field of addiction who are interested in applying their novel approaches to the chemistry and pharmacology of addiction are encouraged to apply.

 

Application Due Date: August 09, 2023

Link to the RFA: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-007.html

 

---------------------------------------------------------------------------------------------

 

IV.                Mechanisms and Targets at the Intersection of HIV and Substance Use (R01 Clinical Trials Not Allowed) (RFA-DA-24-013)

 

The purpose of this Funding Opportunity Announcement (FOA) is to support research on the discovery and development of novel chemical and biological approaches to prevent and/or treat central nervous system (CNS) complications associated with HIV infection and substance use. NIDA is specifically interested in supporting basic research on signaling pathways, virus-host protein interactions, and post-translational protein modifications, which are commonly affected by HIV and substance use and lead to neuropathology and neurocognitive dysfunction.

 

Application Due Date: August 09, 2023

Link to the RFA: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-013.html

 

--------------------------------------------------------------------------------------------

 

V.                  Mechanisms and Targets at the Intersection of HIV and Substance Use (R21 Clinical Trials Not Allowed) (RFA-DA-24-014)

 

The purpose of this Funding Opportunity Announcement (FOA) is to support research on the discovery and development of novel chemical and biological approaches to prevent and/or treat central nervous system (CNS) complications associated with HIV infection and substance use. NIDA is specifically interested in supporting basic research on signaling pathways, virus-host protein interactions, and post-translational protein modifications, which are commonly affected by HIV and substance use and lead to neuropathology and neurocognitive dysfunction.

 

Application Due Date: August 09, 2023

Link to the RFA: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-014.html

 

---------------------------------------------------------------------------------------------

 

VI.                Notice of Special Interest (NOSI) Targeting Epigenetic Regulators for Treating Addiction and Substance Use Disorders (NOT-DA-24-004)

 

The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform applicants about NIDA's special interest in innovative research that uses chemical and pharmacological approaches to identify and target epigenetic regulators and mechanisms for the treatment of addiction and substance use disorders.

 

Link to the Notice: https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-004.html

 

-----------------------------------------------------------------------------------------------

 

VII.              Notice of Special Interest (NOSI): Chemoproteomic Approaches for Discovery of Targets and Therapeutics to Treat Substance Use Disorders (NOT-DA-24-005)

 

The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in supporting basic research on the application of chemoproteomic approaches for the discovery of targets and for development of drugs to treat addiction and substance use disorders.

 

Link to the Notice: https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-005.html

 

-----------------------------------------------------------------------------------------------

 

VIII.            Targeting Inflammasomes in Substance Abuse and HIV (R01 and R21, Clinical Trial Not Allowed). (RFA-DA-24-003) and (RFA-DA-24-004)

 

This FOA supports studies to either (1) elucidate the mechanisms of inflammasomes in virus and drug-induced immune activation, or (2) identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among individuals with SUD. 

RFA-DA-24-003 (Application deadline: March 16, 2023)

RFA-DA-24-004 (Application deadline: March 15, 2023)

 

--------------------------------------------------------------------------------------------------------------------------

 

IX.                Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed) (RFA-DA-24-002)

 

This FOA supports exploratory studies that 1) develop or apply novel tools or technologies or 2) test novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of SUDs.

RFA-DA-24-002 (Application deadline: March 23, 2023)

 

-----------------------------------------------------------------------------------------------------------------------------

X.                  Other NIDA Funding Opportunities - National Institute on Drug Abuse

https://nida.nih.gov/funding/nida-funding-opportunities

 

See NIDA's Resources for Grants & Contracts to learn more about applying for a grant and the pre-approval and approval process. The NIDA Racial ...

‎National Institute on Drug... · ‎NIDA Funding Strategy · ‎FY22 Priority Research Areas

 

 

-------------------------------------------------------------------------------------------------------------------------------

 

XI.                NIDA Division of Therapeutics and Medical Consequences (DTMC) Supervisory Health Scientist Administrator (Branch Chief) Substance Use Disorders 

 

The NIDA DTMC is seeking an exceptional candidate for a Supervisory Health Scientist Administrator (Branch Chief) position focused on research of novel therapeutic approaches for Substance Use Disorders (SUD). DTMC administers a research portfolio of grants and contracts that includes the identification and evaluation of the efficacy and/or safety of medications, devices, digital, behavioral, or other therapeutic interventions for SUDs, and the medical consequences of SUDs.

 

The Supervisory Health Scientist Administrator will provide authoritative advice and guidance on highly technical matters and therapeutic strategies pertaining to the development of treatments for opioid, stimulant (cocaine and methamphetamine), cannabis, and nicotine use disorders and overdose. The ideal candidate should have an advanced degree in medicine, psychology, pharmacology, biochemistry, or biomedical related field.

 

How to apply? Please apply to the Supervisory HSA job announcement links below.  The announcement is open from January 18^th – January 27th, 2023.

 

Delegated Examining (Open to the Public)

 

• GS-12/13/14 Health Scientist Administrator (Program Officer/Scientist Review Officer)
• GS-15 Non-Supervisory Health Scientist Administrator (Program Officer/Scientific Review Officer)
• GS-15 Supervisory Health Scientist Administrator (Program Officer/Scientific Review Officer)

 

Merit Promotion (Open to Status Candidates)

 

• GS-12/13/14 Health Scientist Administrator (Program Officer/Scientific Review Officer)  
• GS-15 Non-Supervisory Health Scientist Administrator (Program Officer/Scientific Review Officer)
• GS-15 Supervisory Health Scientist Administrator (Program Officer/Scientific Review Officer)

 

 

---------------------------------------------------------------------------------------------------

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L  If unable to add or remove yourself from listserv contact Jonathan D. Pollock, Ph.D.  jpollock@mail.nih.gov